Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    RO   CH0012032113


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Roche : Genentech's Tecentriq Improves Overall Survival as a First-Line Monotherapy in Certain People with Advanced Non-Small Cell Lung Cancer

share with twitter share with LinkedIn share with facebook
09/30/2019 | 07:11am EDT

South San Francisco - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the Phase III IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

The study met its primary endpoint in an interim analysis showing that Tecentriq monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy alone (median OS=20.2 versus 13.1 months; hazard ratio [HR]=0.595, 95% CI: 0.398-0.890; p=0.0106) in people with high PD-L1 expression (TC3/IC3-WT). Encouraging OS (18.2 versus 14.9 months; HR=0.717, 95% CI: 0.520-0.989) was also observed in people with medium levels of PD-L1 expression (TC2/3 or IC2/3-WT), however these data did not reach statistical significance at this interim analysis. The study will continue to final analysis for people with lower levels of PD-L1 expression. Safety for Tecentriq appeared to be consistent with its known safety profile, and no new safety signals were identified.

'We are excited to share these positive data, showing that Tecentriq alone offers a significant survival benefit over chemotherapy as an initial treatment in people with squamous or non-squamous non-small cell lung cancer with high PD-L1 expression,' said Sandra Horning, M.D., chief medical officer and head of Global Product Development. 'The IMpower110 results demonstrate the potential of first-line Tecentriq monotherapy in certain types of advanced lung cancer, and could provide an additional treatment option for oncologists and the patients that they treat.'

These data will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress on Friday, September 27, 2019 from 4:00 - 5:30 p.m. CEST (Abstract LBA78; Barcelona Auditorium - Hall 2).

Genentech will submit these data to global health authorities, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and will discuss how best to bring this option to patients as quickly as possible.

Currently, Genentech has nine Phase III lung cancer studies underway evaluating Tecentriq as a monotherapy or in combination with other medicines across different types of lung cancer. Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMpower110 study

IMpower110 is a Phase III, randomized, open-label study to evaluate the efficacy and safety of Tecentriq monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with advanced non-squamous or squamous NSCLC without ALK or EGFR mutations (wild-type; WT).

A total of 572 people (555 WT) were enrolled and were randomized 1:1 to receive: Tecentriq monotherapy, until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity or death; or Cisplatin or carboplatin (per investigator discretion) combined with either pemetrexed (non-squamous) or gemcitabine (squamous), followed by maintenance therapy with pemetrexed alone (non-squamous) or best supportive care (squamous) until disease progression, unacceptable toxicity or death.

The primary efficacy endpoint is OS by PD-L1 subgroup (TC3/IC3-WT; TC2/3/ IC2/3-WT and TC1,2,3/IC1,2,3-WT), as determined by the SP142 assay test. Key secondary endpoints include investigator-assessed progression-free survival (PFS), objective response rate (ORR) and duration of response (DoR).

About lung cancer

According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2019, and NSCLC accounts for 80-85% of all lung cancers. It is estimated that approximately 60% of lung cancer diagnoses in the United States are made when the disease is in the advanced stages.

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Genentech in personalized cancer immunotherapy

For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, we're investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is studying more than 10 cancer immunotherapy medicines across 70 clinical trials alone or in combination with other medicines. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines.

About Genentech in lung cancer

Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.


Tel: (650) 467-6800

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on ROCHE HOLDING AG
2019ROCHE : presents positive Phase III results for Tecentriq® (atezolizumab) in com..
2019ROCHE : Genentech - FDA approves first treatment for children with rare diseases..
2019ROCHE : FDA Approves Genentech's Rituxan in Children with Two Rare Blood Vessel ..
2019ROCHE : Genentech to Present Results of First Prospective Trial Using Blood-Base..
2019ROCHE : Genentech's Tecentriq Improves Overall Survival as a First-Line Monother..
2019U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics
2019NATERA : Foundation Medicine and Natera Partner to Advance Personalized Cancer M..
2019CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication and Formulati..
2019HUADONG MEDICINE : China Anti-Obesity Prescription Drugs Market Research Report ..
2019CHUGAI PHARMACEUTICAL : Receives Orphan Drug Designation for Satralizumab in Neu..
More news
Sales 2020 62 691 M 66 672 M 66 672 M
Net income 2020 15 160 M 16 123 M 16 123 M
Net cash 2020 1 848 M 1 965 M 1 965 M
P/E ratio 2020 19,1x
Yield 2020 2,82%
Capitalization 283 B 301 B 301 B
EV / Sales 2019
EV / Sales 2020 4,49x
Nbr of Employees 97 735
Free-Float 83,7%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 23
Average target price 379,79 CHF
Last Close Price 332,95 CHF
Spread / Highest target 25,2%
Spread / Average Target 14,1%
Spread / Lowest Target -2,39%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG6.70%299 642
JOHNSON & JOHNSON-2.07%377 458
ROCHE HOLDING AG5.27%299 642
MERCK & CO., INC.-14.33%196 678
NOVARTIS AG-10.23%193 644
PFIZER, INC.-13.86%187 476